CNP 108
Alternative Names: CNP-108Latest Information Update: 20 Sep 2022
Price :
$50 *
At a glance
- Originator Cour Pharmaceutical Development
- Class Recombinant proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Immunological disorders
Most Recent Events
- 13 Sep 2022 Preclinical trials in Immunological disorders in USA (Parenteral) (Cour Pharmaceutical Development pipeline; September 2022)